Antivenoms. A review of current status and future developments

BioDrugs

Volumn 7, Issue 5, 1997, Pages 366-375

  Theakston, R David G ^a   Smith, Damon C ^b  

^a LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN F(AB) FRAGMENT; VENOM ANTISERUM;

ANAPHYLAXIS; ARTICLE; DRUG CLEARANCE; DRUG EFFICACY; DRUG MANUFACTURE; DRUG PURIFICATION; DRUG QUALITY; DRUG STABILITY; DRUG STORAGE; HORSE; HUMAN; IMMUNOTHERAPY; NONHUMAN; PRIORITY JOURNAL; SHEEP; TECHNIQUE;

EID: 0030854743     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199707050-00004     Document Type: Article

References (53)

1. World Health Organization. Progress in the characterization of venoms and standardization of antivenoms. WHO Offset Publication No. 58. Geneva: World Health Organization, 1981
2. Theakston RDG, Warrell DA. Antivenoms: a list of hyperimmune sera currently available for the treatment of envenoming by bites and stings. Toxicon 1991; 29: 1419-70
3. Latifi M. Commercial production of commercial anti-snakebite serum (antivenin). In: Gans C, Gans KA, editors. Biology of the reptilia. Vol.8. Physiology. London: Academic Press, 1978: 561
4. Christensen PA. South African snake venoms and antivenoms. Johannesburg: South African Institute for Medical Research, 1955
5. Sawai Y, Chinzei H, Kawamura Y, et al. Studies on the improvement of treatment of Habu (Trimeresurus flavoviridis) bites. IX. Studies on the immunogenicity of the purified habu venom toxoid by alcohol precipitation. Jpn J Exp Med 1972; 42: 155-64
6. Theakston RDG, Smith DC. Therapeutic antibodies to snake venoms. In: Landon J, Chard T, editors. Therapeutic antibodies. London: Springer, 1995: 109-33
7. Christensen PA. The preparation and purification of antivenoms. Mem Inst Butantan 1966; 33: 245-50
8. Amies CR. The use of topically formed calcium alginate as a depot substance in active immunisation. J Pathol Bacteriol 1959; 77: 435-42
9. Christensen PA. Venom and antivenom potency estimation. Mems Inst Butantan 1966; 33: 305-26
10. Grasset E, Christensen PA. Enzyme purification of polyvalent antivenine. South and Equatorial African colubrine and viperine venoms. Trans R Soc Trop Med Hyg 1947; 41: 207-11
11. Latifi M, Manhouri H. Antivenin production. Mem Inst Butantan 1966; 33: 893-7
12. Hartman LJ, Sutherland SK. Funnel-web spider (Atrax robustus) antivenom in the treatment of human envenomation. Med J Aust 1984; 141: 769-99
13. Jerne NK, Perry WLM. The stability of biological standards. Bull World Health Organ 1956; 14: 167-82
14. Christensen PA. The stability of refined antivenom. Toxicon 1975; 13: 75-7
15. World Health Organization. 23rd Report of the WHO Expert Committee on Biological Standardization. Geneva: World Health Organization, 1971. WHO Technical Report Series No. 463
16. Adler FL. Antibody formation after injection of heterologous immunoglobulin. II. Competition of antigens. J Immunol 1957; 78: 201-10
17. Warrell DA, Looareesuwan S, Theakston RDG, et al. Randomised comparative trial of three monospecific antivenoms for bites by the Malayan pit viper (Calloselasma rhodostoma) in southern Thailand: clinical and laboratory correlations. Am J Trop Med Hyg 1986; 35: 1235-47
18. Russell FE, Timmerman WF, Meadows P. Clinical use of antivenin prepared from goal serum. Toxicon 1970; 8: 63-5
19. Kochalty WF, Bowles-Ledford E, Daly JG, et al. Preparation of coral snake antivenom from goat serum. Toxicon 1971; 9: 297-8
20. Russell FE. Use of Crotalus monovalent antivenom from rabbit serum. Curr Ther Res 1961; 3: 438-40
21. Thalley BS, Carroll SB. Rattlesnake and scorpion antivenoms from the egg yolks of immunized hens. Biotechnology 1990; 8: 934-8
22. Carroll SB, Thalley BS, Theakston RDG, et al. A comparison of the purity and efficacy of affinity purified avian antivenoms with commercial equine crotalid antivenoms. Toxicon 1992; 30: 1017-25
23. Russell FE, Sullivan JB, Egan NB, et al. Preparation of a new antivenom by affinity chromatography. Am J Trop Med Hyg 1985; 34: 141-50
24. Weir RC, Porter RR. Comparison of the structure of the immunoglobulins from horse serum. Biochem J 1966; 100: 53-8
25. Cartledge C, Mclean C, Landon J. Production of polyclonal antibodies in ascitic fluid of mice: time and dose relationships. J Immunoassay 1992; 13: 339-53
26. Smith DC, Reddi KR, Laing G, et al. An affinity purified ovine antivenom for the treatment of Vipera berus envenoming. Toxicon 1992; 30: 865-71
27. Al-Joufi A, Bailey GS, Reddi K, et al. Neutralisation of kinin-releasing enzymes from viperid venoms by antivenom IgG fragments. Toxicon 1991; 29: 1509-12
28. Lalloo DA, Trevett AJ, Korinhona A, et al. Snake bites by the Papuan taipan (Oxyuranus scutellatus canni): paralysis, hemostatic and electrocardiographic abnormalities, and effects of antivenom. Am J Trop Med Hyg 1995; 52: 525-31
29. Choumet V, Audebert F, Riviere G, et al. Toxicokinetics of envenomations and antivenom [abstract]. In: Proceedings of the First International Congress on Envenomations and their Treatments; 1995 Jun 7-9. Paris: Institut Pasteur, 1995: 71
30. Landon J, Chard T, Coxon RE. An introduction to the clinical applications of antibodies. In: Landon J, Chard T, editors. Therapeutic antibodies. London: Springer, 1995: 1-32
31. Theakston RDG. New techniques in antivenom production and active immunisation against snake venoms. Trans R Soc Trop Med Hyg 1989; 83: 433-5
32. Reid HA. Symptomatology, pathology and treatment of land snake bile in India and Southeast Asia. In: Bücherl W, Buckley EE, Deulofeu V, editors. Venomous animals and their venoms. Vol. 1. Venomous vertebrates. New York: Academic Press, 1968: 611-42
33. Cardoso JLC, Fan HW, França FOS, et al. Randomized comparative trial of three antivenoms in the treatment of envenoming by lance-headed viper (Bothrops jararaca) snakes in São Paulo, Brazil. Q J Med 1993; 86: 315-25
34. Malasit P, Warrell DA, Chanthavanich P, et al. Prediction, prevention and mechanism of early (anaphylactic) antivenom reactions in victims of snake bites. BMJ 1986; 292: 17-20
35. Antivenom therapy and reactions [editorial]. Lancet 1980; 1: 1009-10
36. Sutherland SK. Serum reactions: an analysis of commercial antivenoms and the possible role of anticomplementary activity in de novo reactions to antivenoms and antitoxins. Med J Aust 1977; 1: 613-5
37. Pugh RNH, Theakston RDG. Antivenom reactions and complement depletion in snake bite. Ann Trop Med Parasitol 1987; 81: 73-5
38. 2 fragments. Toxicon 1994; 32: 725-34
39. Fan HW, Mendes LP, França FOS, et al. Lack of efficacy of antihistamine in preventing early reactions to horse antivenom administration: a retrospective study [abstract]. In: Proceedings of the First International Congress on Envenomations and their Treatments; 1995 Jun 7-9. Paris: Institut Pasteur, 1985: 207
40. Tibballs J. Premedication for snake antivenom. Med J Aust 1994; 160: 4-7
41. Theakston RDG, Reid HA. Development of simple standard assay procedures for the characterization of snake venoms. Bull World Health Organ 1983; 61: 949-56
42. Laing GD, Lee L, Smith DC, et al. Experimental assessment of a new, low-cost antivenom for treatment of carpet viper (Echis ocellatus) envenoming. Toxicon 1995; 33: 307-313
43. Theakston RDG. Characterization of venoms and standardization of antivenoms. In: Harris JB, editor. Natural toxins, animal, plant and microbial. Oxford: Clarendon Press, 1986: 287-303
44. Theakston RDG, Reid HA. Enzyme-linked immunosorbent assay (ELISA) in assessing antivenom potency. Toxicon 1979; 17: 511-5
45. Warrell DA, Davidson NMcD, Ormerod LD, et al. Bites by the saw-scaled or carpet viper (Echis carinatus): trial of two specific antivenoms. BMJ 1974; 4: 437-40
46. Warrell DA, Warrell MJ, Edgar W, et al. Comparison of Pasteur and Behringwerke antivenoms in envenoming by the carpet viper (Echis carinatus). BMJ 1980; 1: 607-9
47. Jorge MT, Cardoso JLC, Castro SCB, et al. A randomised blinded comparison of two doses of antivenom in the treatment of Bothrops envenoming in São Paulo, Brazil. Trans R Soc Trop Med Hyg 1995; 89: 111-4
48. Meyer WP, Habib HG, Onayade AA, et al. First clinical experiences with a new ovine Fab Echis ocellatus snakebite antivenom in Nigeria: randomised comparative trial with Pasteur Ipser Africa antivenom. Am J Trop Med Hyg. In press
49. Theakston RDG, Lloyd-Jones JM, Reid HA. Micro-ELISA for detecting and assaying snake venom and venom antibody. Lancet 1977; II: 639-41
50. Coulter AR, Cox JC, Sutherland SK, et al. A new solid-phase sandwich radioimmunoassay and its application to the detection of snake venom. J Immunol Methods 1978; 23: 242-52
51. Coulter AR, Harris RD, Sutherland SK. Enzyme immunoassay for the rapid identification of snake venom. Med J Aust 1980; 1: 433-5
52. Ho M, Warrell MJ, Warrell DA, et al. A critical reappraisal of the use of enzyme-linked immunosorbent assays in the study of snake bite. Toxicon 1986; 24: 211-21
53. Theakston RDG, Fan HW, Warrell DA, et al. Use of enzyme immunoassays to compare the effect and assess dosage regimens of three Brazilian Bothrops antivenoms. Am J Trop Med Hyg 1992; 47: 593-604